 |
PDBsum entry 4j1c
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
4j1c
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Hydrolase/hydrolase inhibitor
|
|
|
Title:
|
|
Crystal structure of bace-1 in complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-5,5-difluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide
|
|
Structure:
|
|
Beta-secretase 1. Chain: a. Synonym: aspartyl protease 2, asp2, asp 2, beta-site amyloid precursor protein cleaving enzyme 1, beta-site app cleaving enzyme 1, memapsin-2, membrane-associated aspartic protease 2. Engineered: yes. Mutation: yes
|
|
Source:
|
|
Homo sapiens. Human. Organism_taxid: 9606. Gene: bace1, bace, kiaa1149. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
|
|
2.01Å
|
R-factor:
|
0.169
|
R-free:
|
0.217
|
|
|
Authors:
|
|
A.Kuglstatter,M.Stihle
|
|
Key ref:
|
|
H.Hilpert
et al.
(2013).
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
J Med Chem,
56,
3980-3995.
PubMed id:
DOI:
|
|
|
Date:
|
|
|
01-Feb-13
|
Release date:
|
01-May-13
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
P56817
(BACE1_HUMAN) -
Beta-secretase 1 from Homo sapiens
|
|
|
|
Seq:
Struc:
|
|
|
|
501 a.a.
371 a.a.*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
*
PDB and UniProt seqs differ
at 1 residue position (black
cross)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
J Med Chem
56:3980-3995
(2013)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease.
|
|
H.Hilpert,
W.Guba,
T.J.Woltering,
W.Wostl,
E.Pinard,
H.Mauser,
A.V.Mayweg,
M.Rogers-Evans,
R.Humm,
D.Krummenacher,
T.Muser,
C.Schnider,
H.Jacobsen,
L.Ozmen,
A.Bergadano,
D.W.Banner,
R.Hochstrasser,
A.Kuglstatter,
P.David-Pierson,
H.Fischer,
A.Polara,
R.Narquizian.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to
lower the pKa and thereby dramatically change the pharmacological profile of
this class of BACE1 inhibitors. The CF3 substituted oxazine 89, a potent and
highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF
Aβ40 and 42 in rats at oral doses as low as 1 mg/kg. The effect was long
lasting, showing a significant reduction of Aβ40 and 42 even after 24 h. In
contrast to 89, compound 1b lacking the CF3 group was virtually inactive in vivo.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
